Skip to content
Tuesday 28 July 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
City PM

European business, markets and politics

FTSE 100
10,781.75
+0.42%
DAX
25,361.03
0.00%
CAC 40
8,406.06
0.00%
STOXX 50
6,282.21
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sponsored Ad Feature is produced by an advertiser with the specific intent to promote a product and is not produced by the City PM team.
Wednesday 29 December 2021 9:00 am  |  Updated:  Friday 24 December 2021 9:48 am

Harness the power of high-tech skin treatments

By:

Add as a preferred source on Google

Endolift is a minimally invasive laser treatment that aims to stimulate deep and surface skin layers alike, in the process tightening and retracting the connective septum.

The combined diode laser device functions as a non-surgical facelift, improving the appearance of skin. The treatment is FDA-approved, doctor-led and suitable for all skin types. Furthermore, it can be used on multiple areas of the face and body.

Book your free consultation online today at pulselightclinic.co.uk/endolift-treatment 

Read more

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Life&Style

Categories

  • Life&Style

Trending Articles

  • Big Four’s AIM exodus accelerates as mid-tier firms seize mandates

  • FTSE 100 firm agrees £5.7bn takeover in latest private equity swoop

  • Burnham backs plan to pump £1bn pension funds into start-ups

  • Scotland’s tax hike may have backfired as receipt falls

  • As it happened: Stocks rise; oil falls after Trump pauses Iran strikes

More from City PM

  • Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

    Business Wire
  • Almirall H1 2026 Results

    Business Wire
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • UK’s biggest pub firm probed over treatment of tenants

    Hospitality
    Stonegate street scene with historic architecture, bustling crowds, and local shops, capturing vibrant city life ambiance.
  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
CityPM

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About City PM
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 City PM Ltd · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook